

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 58245

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in *db/db* diabetic mice

Klimontov VV *et al.* Empagliflozin alleviates podocytopathy in *db/db* diabetic mice

Vadim V Klimontov, Anton I Korbuto, Iuliia S Taskaeva, Nataliya P Bgatova, Maksim V Dashkin, Nikolay B Orlov, Anna S Khotskina, Evgenii L Zavyalov, Thomas Klein

Match Overview

1	Internet 143 words crawled on 25-Jul-2020 www.mdpi.com	3%
2	Crossref 51 words Anton I. Korbuto, Iuliia S. Taskaeva, Nataliya P. Bgatova, Nataliya A. Muraleva et al. "SGLT2 Inhibitor Empagliflozin an	1%
3	Crossref 35 words Anton Korbuto, Vadim. Klimontov, Iuliia Taskaeva, Nataliya Bgatova, Evgenij Zavyalov. "Empagliflozin and linagliptin	1%
4	Crossref 26 words "Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment", Springer Science and Bu	1%
5	Internet 20 words crawled on 13-Sep-2015 onlinelibrary.wiley.com	<1%
6	Internet 20 words crawled on 18-Sep-2020 ideas.repec.org	<1%
7	Internet 19 words	<1%

ALL

IMAGES

VIDEOS

1,260 Results

Any time ▾

(PDF) Empagliflozin and linagliptin alleviate podocyte ...

https://www.researchgate.net/publication/329879545_Empagliflozin_and_linagliptin...

Oct 05, 2018 · Conclusion: The data from the current study demonstrate that **DPP-4 inhibitor linagliptin ameliorates podocyte injury and enhances glomerular expression of nephrin** in a model of type 2 diabetic ...

IJMS | Free Full-Text | SGLT2 Inhibitor Empagliflozin and ...

<https://www.mdpi.com/1422-0067/21/8/2987/htm> ▾

Identifying the renal effects of these drugs is a challenge to modern medicine. In our study, we demonstrated that both empagliflozin, a **SGLT2 inhibitor**, and **linagliptin**, a **DPP4 inhibitor**, **attenuate diabetic kidney disease by promoting glomerular autophagy** in **db/db mice**, a model of type 2 diabetes.

Cited by: 8

Author: Anton I Korbut, Iuliia S Taskaeva, Nataliy...

Publish Year: 2020

Dapagliflozin attenuates early markers of diabetic ...

<https://www.sciencedirect.com/science/article/pii/S0753332218348406>

Jan 01, 2019 · On the contrary, a recent study suggested that the increased markers for tubular damage, KIM-1 and NGAL were not affected by the selective SGLT2 inhibitor, empagliflozin, in spite of improved glycemic control, suppressed **TGF-β** and **mitigated histological markers of renal fibrosis in db/db mice** . This discrepancy might be attributed to the extent of the blood glucose ...

Cited by: 5

Author: Mamdouh A. Oraby, Mohammed F. El-Ya...

Publish Year: 2019

Empagliflozin alleviates renal inflammation and oxidative ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535193>

Materials and Methods: **Empagliflozin** at 10 mg/kg per os (p.o.) was administered for 4 weeks, starting 8

Empagliflozin alleviates podocytopathy and enhances glomerular n



ALL

IMAGES

VIDEOS

2,760 Results

Any time ▾

(PDF) Empagliflozin and linagliptin alleviate podocyte ...

<https://www.researchgate.net/publication/329879545...>

May 01, 2020 · Conclusion: The data from the current study demonstrate that **DPP-4 inhibitor linagliptin ameliorates podocyte injury and enhances glomerular expression of nephrin** in a model of type 2 diabetic ...

Dapagliflozin attenuates early markers of diabetic ...

<https://www.sciencedirect.com/science/article/pii/S0753332218348406>

Jan 01, 2019 · On the contrary, a recent study suggested that the increased markers for tubular damage, KIM-1 and NGAL were not affected by the selective SGLT2 inhibitor, empagliflozin, in spite of improved glycemic control, suppressed **TGF- β and mitigated histological markers of renal fibrosis in db/db mice**. This discrepancy might be attributed to the extent of the blood glucose lowering caused by the ...

Cited by: 5

Author: Mamdouh A. Oraby, Mohammed F. El-Yama...

Publish Year: 2019

IJMS | Free Full-Text | SGLT2 Inhibitor Empagliflozin and ...

<https://www.mdpi.com/1422-0067/21/8/2987/htm> ▾

Identifying the renal effects of these drugs is a challenge to modern medicine. In our study, we

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

2,770 Results

Any time ▾

(PDF) Empagliflozin and linagliptin alleviate podocyte ...

<https://www.researchgate.net/publication/329879545...>

May 01, 2020 · Conclusion: The data from the current study demonstrate that **DPP-4 inhibitor linagliptin ameliorates podocyte injury and enhances glomerular expression of nephrin** in a model of type 2 diabetic ...

Dapagliflozin attenuates early markers of diabetic ...

<https://www.sciencedirect.com/science/article/pii/S0753332218348406>

Jan 01, 2019 · On the contrary, a recent study suggested that the increased markers for tubular damage, KIM-1 and NGAL were not affected by the selective SGLT2 inhibitor, empagliflozin, in spite of improved glycemic control, suppressed **TGF- β and mitigated histological markers of renal fibrosis in db/db mice**. This discrepancy might be attributed to the extent of the blood glucose lowering caused by the ...

Cited by: 5

Author: Mamdouh A. Oraby, Mohammed F. El-Ya...

Publish Year: 2019

IJMS | Free Full-Text | SGLT2 Inhibitor Empagliflozin and ...

<https://www.mdpi.com/1422-0067/21/8/2987/htm> ▾

Identifying the renal effects of these drugs is a challenge to modern medicine. In our study, we demonstrated that both empagliflozin, a **SGLT2 inhibitor**, and **linagliptin**, a **DPP4 inhibitor**, **attenuate diabetic kidney disease by promoting glomerular autophagy in db/db mice**, a ...

Cited by: 7

Author: Anton I Korbut, Iuliia S Taskaeva, Nataliy...

Publish Year: 2020

Linagliptin alleviates podocyte injury and enhances ...

<https://www.researchgate.net/publication/320149611...>

Conclusion: The data from the current study demonstrate that **DPP-4 inhibitor linagliptin ameliorates podocyte injury and enhances glomerular expression of nephrin** in a model of type 2 diabetic ...